Maxime Fayon
Overview
Explore the profile of Maxime Fayon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
36
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Roders N, Nakid-Cordero C, Raineri F, Fayon M, Abecassis A, Choisy C, et al.
Cancer Immunol Res
. 2024 Jan;
12(4):478-490.
PMID: 38289260
Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma targeting B-cell maturation antigen (BCMA) induces high overall response rates. However, relapse still occurs and novel strategies for targeting multiple myeloma...
2.
Causeret F, Fayon M, Moreau M, Ne E, Oleari R, Parras C, et al.
J Comp Neurol
. 2023 May;
531(12):1229-1243.
PMID: 37125418
In vertebrates, the embryonic olfactory epithelium contains progenitors that will give rise to distinct classes of neurons, including olfactory sensory neurons (OSNs; involved in odor detection), vomeronasal sensory neurons (VSNs;...
3.
Abecassis A, Roders N, Fayon M, Choisy C, Nelson E, Harel S, et al.
EJHaem
. 2022 Sep;
3(3):970-974.
PMID: 36051036
Chimeric antigen receptor T cells (CAR-T) have provided promising results in multiple myeloma (MM). However, many patients still relapse, pointing toward the need of improving this therapy. Here, we analyzed...
4.
Fayon M, Martinez-Cingolani C, Abecassis A, Roders N, Nelson E, Choisy C, et al.
Haematologica
. 2020 Jul;
106(4):1193-1197.
PMID: 32675220
No abstract available.